Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Liu is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineResidency, Pathology-Anatomic and Clinical, 1994 - 1999
Shanghai Medical UniversityClass of 1983
Certifications & Licensure
TX State Medical License 2000 - 2028
American Board of Pathology Anatomic Pathology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Publications & Presentations
PubMed
- A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.Lauren P Cobb, Yibo Dai, Max Molina Ayala, Nejla Ozirmak Lermi, Sharia D Hernandez
Nature Communications. 2026-06-29 - Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights.Allison L Brodsky, Amma Asare, Bryan Fellman, Kristin Anderson, Jun Yao
Clinical Cancer Research. 2026-04-01 - 1 citationsThe association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvan...Roni Nitecki Wilke, Jinsong Liu, Shannon Neville Westin, Bryan M Fellman, Travis T Sims
International Journal of Gynecological Cancer. 2025-11-01
Journal Articles
- FABP4 as a Key Determinant of Metastatic Potential of Ovarian CancerJinsong Liu, Anil K Sood, Nature
Press Mentions
Targeted Biologic Inhibition of Both Tumor Cell-Intrinsic and Intercellular CLPTM1L/CRR9-mediated Chemotherapeutic Drug ResistanceMarch 2nd, 2021
MD Anderson Research Highlights for August 2, 2023August 3rd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
